Abstract
Depression is a major health issue, which is routinely treated with selective serotonin reuptake inhibitors. However, although these agents display a favorable effect on mood, they often fail to improve conditions that accompany depression including cognitive impairment and fatigue. In pre-clinical studies histamine H3 receptor antagonists have demonstrated both pro-cognitive and wake-promoting effects suggesting that the combination of a histamine H3 receptor antagonist and a serotonin reuptake inhibitor may have utility as an antidepressant therapy. To this end we sought to introduce histamine H3 receptor antagonist activity into both known selective serotonin reuptake inhibitors and novel templates. These efforts have afforded several series of compounds with the desired activities. Selected examples demonstrated in vivo efficacy both in pre-clinical models of depression and wakefulness.
Keywords: Histamine, histamine H3 receptor, histamine H3 receptor antagonists, serotonin, serotonin transporter (SERT), norepinephrine transporter (NET), dopamine transporter (DAT), selective serotonin reuptake inhibitors (SSRIs), depression, wakefulness
Current Topics in Medicinal Chemistry
Title: Exploration of Structure-Activity Relationships for Dual Serotonin Transporter Reuptake Inhibitors-Histamine H3 Receptor Antagonists
Volume: 10 Issue: 5
Author(s): Emily M. Stocking, Michael A. Letavic, Pascal Bonaventure and Nicholas I. Carruthers
Affiliation:
Keywords: Histamine, histamine H3 receptor, histamine H3 receptor antagonists, serotonin, serotonin transporter (SERT), norepinephrine transporter (NET), dopamine transporter (DAT), selective serotonin reuptake inhibitors (SSRIs), depression, wakefulness
Abstract: Depression is a major health issue, which is routinely treated with selective serotonin reuptake inhibitors. However, although these agents display a favorable effect on mood, they often fail to improve conditions that accompany depression including cognitive impairment and fatigue. In pre-clinical studies histamine H3 receptor antagonists have demonstrated both pro-cognitive and wake-promoting effects suggesting that the combination of a histamine H3 receptor antagonist and a serotonin reuptake inhibitor may have utility as an antidepressant therapy. To this end we sought to introduce histamine H3 receptor antagonist activity into both known selective serotonin reuptake inhibitors and novel templates. These efforts have afforded several series of compounds with the desired activities. Selected examples demonstrated in vivo efficacy both in pre-clinical models of depression and wakefulness.
Export Options
About this article
Cite this article as:
Stocking Emily M., Letavic Michael A., Bonaventure Pascal and Carruthers Nicholas I., Exploration of Structure-Activity Relationships for Dual Serotonin Transporter Reuptake Inhibitors-Histamine H3 Receptor Antagonists, Current Topics in Medicinal Chemistry 2010; 10 (5) . https://dx.doi.org/10.2174/156802610791111515
DOI https://dx.doi.org/10.2174/156802610791111515 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Modulation of Protein-Protein Interactions as a Therapeutic Strategy for the Treatment of Neurodegenerative Tauopathies
Current Topics in Medicinal Chemistry Editorial: Multi-Target in Computer-Aided Drug Design Studies
Current Drug Targets Tako-tsubo Cardiomyopathy: A Review of the Literature
Current Cardiology Reviews Repetitive Transcranial Magnetic Stimulation to Treat Substance Use Disorders and Compulsive Behavior
CNS & Neurological Disorders - Drug Targets Cell Surface Markers on Adipose-Derived Stem Cells: A Systematic Review
Current Stem Cell Research & Therapy Anesthesia Issues in Central Nervous System Disorders
Current Aging Science Anti-obesity Agents: A Focused Review on the Structural Classification of Therapeutic Entities
Current Topics in Medicinal Chemistry Development of Doxorubicin Quantification by Reductive Amination
Current Analytical Chemistry Molecular Mechanism of Aniline Induced Spleen Toxicity and Neuron Toxicity in Experimental Rat Exposure: A Review
Current Neuropharmacology Vitamin D Biology in Heart Failure: Molecular Mechanisms and Systematic Review
Current Drug Targets Can the Sigma-1 Receptor Agonist Fluvoxamine Prevent Schizophrenia?
CNS & Neurological Disorders - Drug Targets Voltage-Dependent Na+ Channels as Targets of BACE1 - Implications for Neuronal Firing and Beyond
Current Alzheimer Research Current Options and Future Possibilities for the Treatment of Dyskinesia and Motor Fluctuations in Parkinson's Disease
CNS & Neurological Disorders - Drug Targets Elderly Hypertensive Patients: Silent White Matter Lesions, Blood Pressure Variability, Baroreflex Impairment and Cognitive Deterioration
Current Hypertension Reviews Circulating Biomarkers in Migraine: New Opportunities for Precision Medicine
Current Medicinal Chemistry Physicochemical and Pharmacological Characterization of Permanently Charged Opioids
Current Medicinal Chemistry Thin, Stubby or Mushroom: Spine Pathology in Alzheimers Disease
Current Alzheimer Research Editorial [Hot Topic: Stem Cells and Tissue Regeneration (Executive Guest Editor: Roberta Di Pietro)]
Current Pharmaceutical Design RNAi Screening for the Discovery of Novel Modulators of Human Disease
Current Pharmaceutical Biotechnology Role of Calcium Channels in Bipolar Disorder
Current Psychopharmacology